Keith Regnante - Jan 4, 2024 Form 4/A - Amendment Insider Report for Keros Therapeutics, Inc. (KROS)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Keith Regnante
Stock symbol
KROS
Transactions as of
Jan 4, 2024
Transactions value $
-$1,171,600
Form type
4/A - Amendment
Date filed
1/24/2025, 04:15 PM
Date Of Original Report
Jan 8, 2024
Previous filing
Jan 8, 2024
Next filing
Feb 15, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $640K +40K $16.00 40K Jan 4, 2024 Direct F1, F2
transaction KROS Common Stock Sale -$1.81M -40K -100% $45.29 0 Jan 4, 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amendment is being filed to correct the Date of Earliest Transaction and the Transaction Date of each transaction listed in Table I.
F2 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 8, 2023.